MersV1, PubMed, Checkpoint, bibRecord, 001527

Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.

Identifieur interne : 001527 ( PubMed/Checkpoint ); précédent : 001526; suivant : 001528

Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.

Auteurs : Xian-Chun Tang [États-Unis] ; Wayne A. Marasco [États-Unis]

Source :

Immunotherapy [ 1750-7448 ] ; 2015.

RBID : pubmed:26098703

Descripteurs français

KwdFr :
- Anticorps antiviraux (immunologie), Anticorps antiviraux (usage thérapeutique), Anticorps neutralisants (immunologie), Anticorps neutralisants (usage thérapeutique), Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie), Humains, Immunothérapie, Infections à coronavirus (), Infections à coronavirus (immunologie), Portraits comme sujet.
MESH :
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Coronavirus du syndrome respiratoire du Moyen-Orient, Infections à coronavirus.
- usage thérapeutique : Anticorps antiviraux, Anticorps neutralisants.
- Humains, Immunothérapie, Infections à coronavirus, Portraits comme sujet.

English descriptors

KwdEn :
- Antibodies, Neutralizing (immunology), Antibodies, Neutralizing (therapeutic use), Antibodies, Viral (immunology), Antibodies, Viral (therapeutic use), Coronavirus Infections (immunology), Coronavirus Infections (therapy), Humans, Immunotherapy, Middle East Respiratory Syndrome Coronavirus (immunology), Portraits as Topic.
MESH :
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , therapeutic use : Antibodies, Neutralizing, Antibodies, Viral.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- therapy : Coronavirus Infections.
- Humans, Immunotherapy, Portraits as Topic.

DOI: 10.2217/imt.15.33
PubMed: 26098703

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001579
to stream PubMed, to step Curation: 001579

Links to Exploration step

pubmed:26098703

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.</title>
<author><name sortKey="Tang, Xian Chun" sort="Tang, Xian Chun" uniqKey="Tang X" first="Xian-Chun" last="Tang">Xian-Chun Tang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marasco, Wayne A" sort="Marasco, Wayne A" uniqKey="Marasco W" first="Wayne A" last="Marasco">Wayne A. Marasco</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26098703</idno>
<idno type="pmid">26098703</idno>
<idno type="doi">10.2217/imt.15.33</idno>
<idno type="wicri:Area/PubMed/Corpus">001579</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001579</idno>
<idno type="wicri:Area/PubMed/Curation">001579</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001579</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001527</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001527</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.</title>
<author><name sortKey="Tang, Xian Chun" sort="Tang, Xian Chun" uniqKey="Tang X" first="Xian-Chun" last="Tang">Xian-Chun Tang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marasco, Wayne A" sort="Marasco, Wayne A" uniqKey="Marasco W" first="Wayne A" last="Marasco">Wayne A. Marasco</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Immunotherapy</title>
<idno type="eISSN">1750-7448</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Neutralizing (therapeutic use)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibodies, Viral (therapeutic use)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Humans</term>
<term>Immunotherapy</term>
<term>Middle East Respiratory Syndrome Coronavirus (immunology)</term>
<term>Portraits as Topic</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (usage thérapeutique)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Anticorps neutralisants (usage thérapeutique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (immunologie)</term>
<term>Humains</term>
<term>Immunothérapie</term>
<term>Infections à coronavirus ()</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Portraits comme sujet</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Infections à coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Immunotherapy</term>
<term>Portraits as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Immunothérapie</term>
<term>Infections à coronavirus</term>
<term>Portraits comme sujet</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26098703</PMID>
<DateCompleted><Year>2016</Year>
<Month>04</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-7448</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>7</Volume>
<Issue>6</Issue>
<PubDate><Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>Immunotherapy</Title>
<ISOAbbreviation>Immunotherapy</ISOAbbreviation>
</Journal>
<ArticleTitle>Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.</ArticleTitle>
<Pagination><MedlinePgn>591-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2217/imt.15.33</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName>
<ForeName>Xian-Chun</ForeName>
<Initials>XC</Initials>
<AffiliationInfo><Affiliation>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marasco</LastName>
<ForeName>Wayne A</ForeName>
<Initials>WA</Initials>
<AffiliationInfo><Affiliation>Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 AI085524</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01AI085524</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>06</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Immunotherapy</MedlineTA>
<NlmUniqueID>101485158</NlmUniqueID>
<ISSNLinking>1750-743X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011173" MajorTopicYN="N">Portraits as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IGHV1–69</Keyword>
<Keyword MajorTopicYN="N">MERS-CoV</Keyword>
<Keyword MajorTopicYN="N">animal model</Keyword>
<Keyword MajorTopicYN="N">biodefense</Keyword>
<Keyword MajorTopicYN="N">emerging pathogen</Keyword>
<Keyword MajorTopicYN="N">human monoclonal antibodies</Keyword>
<Keyword MajorTopicYN="N">humoral immunity</Keyword>
<Keyword MajorTopicYN="N">passive immunotherapy</Keyword>
<Keyword MajorTopicYN="N">spike protein</Keyword>
<Keyword MajorTopicYN="N">zoonosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>6</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>6</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>4</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26098703</ArticleId>
<ArticleId IdType="pmc">PMC5068219</ArticleId>
<ArticleId IdType="doi">10.2217/imt.15.33</ArticleId>
<ArticleId IdType="mid">NIHMS821915</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367 (19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2013 Oct;19(10 ):1313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2014 Apr 30;6(234):234ra59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24778414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24778221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2008 Nov;4(11):e1000197</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18989460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2014;5:3067</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hong Kong Med J. 2003 Jun;9(3):199-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12777656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jul;88(14):7796-805</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24789777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24062443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2014 Dec;20(12 ):2093-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25425139</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Immunol. 2013;31:705-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23330954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Tang, Xian Chun" sort="Tang, Xian Chun" uniqKey="Tang X" first="Xian-Chun" last="Tang">Xian-Chun Tang</name>
</region>
<name sortKey="Marasco, Wayne A" sort="Marasco, Wayne A" uniqKey="Marasco W" first="Wayne A" last="Marasco">Wayne A. Marasco</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001527 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001527 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26098703
   |texte=   Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26098703" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.

Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy.

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki